Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
Amicus Therapeutics
ISIN US03152W1099
|WKN A0MSMZ
Market cap (in EUR)
3,736 m
Country
United States
Sector
Healthcare
Dividend yield
0.00%
Advertisement
Capital at risk. Execution-only service.
Overview
Description
Amicus Therapeutics, Inc. is a biotechnology company, which focuses on discovering, developing, and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Princeton, NJ.
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals United States
Financials
Key metrics
| Market capitalisation, EUR | 3,736 m |
| EPS, EUR | -0.04 |
| P/B ratio | 19.0 |
| P/E ratio | - |
| Dividend yield | 0.00% |
Income statement (2024)
| Revenue, EUR | 488 m |
| Net income, EUR | -52 m |
| Profit margin | -10.62% |
What ETF is Amicus Therapeutics in?
There are 31 ETFs which contain Amicus Therapeutics. All of these ETFs are listed in the table below. The ETF with the largest weighting of Amicus Therapeutics is the WisdomTree BioRevolution UCITS ETF USD Acc.
Latest articles
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.